$3.95 -0.05 (-1.25%)
12/3/2009 4:00 PM

Amicus Therapeutics, Inc. (FOLD)

CAPS Rating: 2 out of 5

A clinical-stage biopharmaceutical company, which focused on the discovery, development and commercialization of novel small molecule, orally-administered drugs, known as pharmacological chaperones, for the treatment of a range of human genetic diseases.

Current Price $3.95 Mkt Cap $89.46M
Open $0.00 P/E Ratio 11.67
Prev. Close $4.00 Div. (Yield) N/A (N/A)
Daily Range $3.75 - $4.02 Volume 38,226
52-Wk Range $3.21 - $13.50 Avg. Daily Vol. 123,000

FOLD News and Commentary

Related News and Articles

Caps

This ticker is not currently Ratable.

Add Stock to Watchlist

All Members

32 Outperform
14 Underperform
 

All-Star Members

14 Outperform
6 Underperform
 

Wall Street

3 Outperform
1 Underperform
 

Top FOLD Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Top Bull Pitch

There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches below!

PDTBiotech (89.65)
Submitted February 11, 2009

Piling in on zzlangerhans' excellent short call. Could cause significant pain before the woodshed trip due to the current and hopefully temporary lack of natural selection in the biotech industry. Shorts' enemy on this one is Amicus'… More

FOLD VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from members about FOLD.

Recs

0
Member Avatar SmallPimpin (98.29) Submitted: 10/6/2009 7:31:52 PM : Outperform Start Price: $5.26 FOLD Score: -29.76

Mmm...pharmaceuticals...

Recs

0
Member Avatar mansloth (94.47) Submitted: 1/8/2009 8:32:13 PM : Outperform Start Price: $7.92 FOLD Score: -73.35

Therapeutics for protein folding diseases are going to be trendy over the next couple of years. More (and perhaps better) competitors with a focus on protein folding diseases will go public over the course of the next five years, while established ones like this will get gobbled up.

Recs

0
Member Avatar mjan706 (< 20) Submitted: 9/22/2008 1:48:52 AM : Outperform Start Price: $15.21 FOLD Score: -65.03

An Icahn portfolio stock.

Leaderboard

Find the members with the highest scoring picks in FOLD.

Score Leader

epc53

epc53 (99.28) Score: +90.45

The Score Leader is the member with the highest score across all their picks in FOLD.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score Commentary
qubit15 24.84 1/21/2009 Underperform NS $7.91 -50.06% +37.91% +87.98
anticitradeshort 26.33 4/20/2009 Underperform NS $8.75 -54.86% +30.38% +85.24
OOji 98.92 1/12/2009 Underperform 1Y $7.60 -48.03% +26.44% +74.47
BetapegAnalytics 86.12 8/13/2009 Underperform 5Y $9.91 -60.13% +9.81% +69.94
epc53 99.28 5/27/2009 Underperform 5Y $6.90 -42.75% +21.98% +64.73
mmmed 30.71 5/29/2009 Underperform 5Y $6.79 -41.83% +22.01% +63.83
ArmstrongMan 93.09 7/24/2008 11/30/2009 Underperform 1Y $14.92 -73.53% -11.26% +62.27
bmoreNJ 38.87 8/28/2008 Underperform 3M $13.80 -71.38% -12.35% +59.03
PauvrePapillon 99.61 6/26/2007 Underperform 1Y $10.88 -63.69% -22.13% +41.56
SanDieguito < 20 12/20/2007 Underperform 1Y $9.99 -60.46% -20.66% +39.80 1 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackWedbush < 20 10/5/2009 Underperform NS $6.20 -36.29% +7.27% +43.56
TrackWedbush < 20 3/20/2009 Outperform NS $9.24 -32.90% +33.24% -66.14 10/5/2009 @ $6.20
TrackIcahn 23.13 12/31/2007 Outperform NS $10.75 -35.81% -37.65% +1.84 5/27/2009 @ $6.90 2 Comments
TrackPacificGrow 83.75 7/10/2007 Outperform NS $12.88 -69.33% -23.76% -45.57
TrackLazardCapit < 20 7/10/2007 Outperform NS $12.70 -68.90% -23.69% -45.21
TrackJPMorgan 76.55 7/10/2007 Outperform NS $13.00 -69.62% -23.70% -45.91

Featured Broker Partners